Inqovi

Patients

Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.

News

BeOne gets the nod for BCL2 inhibitor Beqalzi in mantle cell lymphoma, while Taiho's Inqovi has acute myeloid leukaemia added to its label.

News

A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.